25 Tex. Admin. Code § 97.3 - What Condition to Report and What Isolates to Report or Submit
(a) Humans.
(1) Identification of notifiable conditions.
(A) A summary list of notifiable conditions
and reporting time frames is published on the Department of State Health
Services web site at
https://www.dshs.texas.gov/idcu/investigation/conditions/.
Copies are filed in the Emerging and Acute Infectious Disease Unit, Department
of State Health Services, 1100 West 49th Street, Austin, Texas 78756.
(B) Repetitive test results from the same
patient do not need to be reported except those for mycobacterial
infections.
(2)
Notifiable conditions or isolates.
(A)
Confirmed and suspected human cases of the following diseases and infections
are reportable:
(i) acquired immune
deficiency syndrome (AIDS);
(ii)
amebic meningitis and encephalitis;
(iii) anaplasmosis;
(iv) ancylostomiasis;
(v) anthrax;
(vi) arboviral infections, including those
caused by California serogroup virus, chikungunya virus, dengue virus, Eastern
equine encephalitis (EEE) virus, St. Louis encephalitis (SLE) virus, Western
equine encephalitis (WEE) virus, yellow fever virus, West Nile (WN) virus, and
Zika virus;
(vii)
ascariasis;
(viii)
babesiosis;
(ix) botulism, adult
and infant;
(x)
brucellosis;
(xi)
campylobacteriosis;
(xii)
Candida auris;
(xiii) carbapenem resistant
Enterobacteriaceae (CRE);
(xiv) Chagas disease;
(xv) chancroid;
(xvi) chickenpox (varicella);
(xvii)
Chlamydia trachomatis
infection;
(xviii)
Cronobacter spp. in infants, invasive;
(xix) cryptosporidiosis;
(xx) cyclosporiasis;
(xxi) diphtheria;
(xxii) echinococcosis;
(xxiii) ehrlichiosis;
(xxiv) fascioliasis;
(xxv) gonorrhea;
(xxvi)
Haemophilus
influenzae, invasive;
(xxvii) Hansen's disease (leprosy);
(xxviii) hantavirus infection;
(xxix) hemolytic uremic syndrome
(HUS);
(xxx) hepatitis, including
hepatitis A, acute hepatitis B infection, hepatitis B acquired perinatally
(child), any hepatitis B infection identified prenatally or at delivery
(mother), acute hepatitis C infection, and acute hepatitis E
infection;
(xxxi) human
immunodeficiency virus (HIV) infection;
(xxxii) influenza-associated pediatric
mortality;
(xxxiii)
legionellosis;
(xxxiv)
leishmaniasis;
(xxxv)
listeriosis;
(xxxvi) Lyme
disease;
(xxxvii)
malaria;
(xxxviii) measles
(rubeola);
(xxxix)
melioidosis;
(xl) meningococcal
infection, invasive;
(xli)
mumps;
(xlii) novel
coronavirus;
(xliii) novel
influenza;
(xliv)
paragonimiasis;
(xlv)
pertussis;
(xlvi) plague;
(xlvii) poliomyelitis, acute
paralytic;
(xlviii) poliovirus
infection, non-paralytic;
(xlix)
prion diseases, such as Creutzfeldt-Jakob disease (CJD);
(l) Q fever;
(li) rabies;
(lii) rubella (including
congenital);
(liii) salmonellosis,
including typhoid fever;
(liv)
Shiga toxin-producing Escherichia coli infection;
(lv) shigellosis;
(lvi) smallpox;
(lvii) spotted fever group rickettsioses
(such as Rocky Mountain spotted fever);
(lviii) streptococcal disease:
Streptococcus pneumoniae, invasive;
(lix) syphilis;
(lx)
Taenia solium and
undifferentiated Taenia infections, including
cysticercosis;
(lxi)
tetanus;
(lxii) tick-borne
relapsing fever;
(lxiii)
trichinosis;
(lxiv)
trichuriasis;
(lxv) tuberculosis
(Mycobacterium tuberculosis complex);
(lxvi) tuberculosis infection;
(lxvii) tularemia;
(lxviii) typhus;
(lxix) vancomycin-intermediate
Staphylococcus aureus (VISA);
(lxx) vancomycin-resistant
Staphylococcus aureus (VRSA);
(lxxi)
Vibrio infection,
including cholera (specify species);
(lxxii) viral hemorrhagic fever;
and
(lxxiii)
yersiniosis.
(B) In
addition to individual case reports, any outbreak, exotic disease, or unusual
group expression of disease that may be of public health concern should be
reported by the most expeditious means.
(3) Minimal reportable information
requirements. The minimal information that must be reported for each disease is
as follows.
(A) AIDS, chancroid,
Chlamydia trachomatis infection, gonorrhea, HIV infection, and
syphilis must be reported in accordance with Subchapter F of this chapter
(relating to Sexually Transmitted Diseases Including Acquired Immune Deficiency
Syndrome (AIDS) and Human Immunodeficiency Virus (HIV)).
(B) For tuberculosis disease - complete name,
date of birth, physical address and county of residence, country of origin, and
information on which diagnosis was based or suspected. In addition, if known,
radiographic or diagnostic imaging results and dates; all information necessary
to complete the most recent versions of department reporting forms: Report of
Case and Patient Services, Report of Follow-up and Treatment for Contacts to TB
Cases and Suspects, and Report of Verified Case of Tuberculosis; laboratory
results used to guide prescribing, monitoring, or modifying antibiotic
treatment regimens for tuberculosis, including liver function studies, renal
function studies, and serum drug levels; pathology reports related to
diagnostic evaluations of tuberculosis; reports of imaging or radiographic
studies; records of hospital or outpatient care, including histories and
physical examinations, discharge summaries, and progress notes; records of
medication administration, including directly observed therapy (DOT) records,
and drug toxicity and monitoring records; a listing of other patient
medications to evaluate the potential for drug-drug interactions; and copies of
court documents related to court-ordered management of tuberculosis.
(C) For contacts to a known case of
tuberculosis - complete name, date of birth, physical address, county of
residence, evaluation and disposition, and all information necessary to
complete the most recent versions of department reporting forms: Report of
Follow-up and Treatment for Contacts to TB Cases and Suspects and Report of
Case and Patient Services.
(D) For
other persons identified with tuberculosis infection - complete name, date of
birth, physical address and county of residence, country of origin, diagnostic
information, treatment information, medical and population risks, and all
information necessary to complete the most recent version of the department's
reporting form, Report of Case and Patient Services.
(E) For hepatitis B (chronic and acute)
identified prenatally or at delivery - mother's name, address, telephone
number, age, date of birth, sex, race and ethnicity, preferred language,
hepatitis B laboratory test results; estimated delivery date or date and time
of birth; name and phone number of delivery hospital or planned delivery
hospital; name of infant; name, phone number, and address of medical provider
for infant; date, time, formulation, dose, manufacturer, and lot number of
hepatitis B vaccine and hepatitis B immune globulin administered to
infant.
(F) For hepatitis A, B, C,
and E - name, address, telephone number, age, date of birth, sex, race and
ethnicity, disease, diagnostic indicators (diagnostic lab results, including
all positive and negative hepatitis panel results, liver function tests, and
symptoms), date of onset, pregnancy status, and physician or practitioner name,
address, and telephone number.
(G)
For hepatitis B, perinatal infection - name of infant; date of birth; sex; race
and ethnicity; name, phone number, and address of medical provider for infant;
date, time, formulation, dose, manufacturer, and lot number of hepatitis B
vaccine and hepatitis B immune globulin administered to infant; and hepatitis B
laboratory test results.
(H) For
chickenpox - name, date of birth, sex, race and ethnicity, address, date of
onset, and varicella vaccination history.
(I) For Hansen's disease - name; date of
birth; sex; race and ethnicity; disease type; place of birth; address;
telephone number; date entered Texas; date entered U.S.; education and
employment; insurance status; location and inclusive dates of residence outside
U.S.; date of onset and history prior to diagnosis; date of initial biopsy and
result; disease type (i.e., tuberculoid, borderline, and lepromatous); date
initial drugs prescribed and name of drugs; name, date of birth, and
relationship of household contacts; and name, address, and telephone number of
physician or practitioner.
(J) For
novel influenza investigations occurring during an influenza pandemic-minimal
reportable information on individual cases, a subset of cases or aggregate data
will be specified by the department.
(K) For all other notifiable conditions
listed in paragraph (2)(A) of this subsection - name, address, telephone
number, age, date of birth, sex, race and ethnicity, disease, diagnostic
indicators (diagnostic lab results, specimen source, test type, and clinical
indicators), date of onset, and physician or practitioner name, address, and
telephone number.
(L) Other
information may be required as part of an investigation in accordance with
Texas Health and Safety Code §
81.061.
(4) Diseases requiring submission of
cultures. Pure cultures, or specimens as indicated below, must be submitted and
accompanied by a current department Specimen Submission Form for:
(A) anthrax (Bacillus
anthracis);
(B) botulism,
adult and infant (Clostridium botulinum);
(C) brucellosis (Brucella
species);
(D)
Candida
auris;
(E) diphtheria
(Corynebacteria diphtheriae from any site);
(F) all Haemophilus
influenzae, invasive, in children under five years old
(Haemophilus influenzae from normally sterile sites);
(G) listeriosis (Listeria
monocytogenes);
(H)
meningococcal infection, invasive (Neisseria meningitidis from
normally sterile sites or purpuric lesions);
(I) plague (Yersinia
pestis);
(J)
salmonellosis, including typhoid fever (Salmonella
species);
(K) Shiga toxin-producing
Escherichia coli infection (E.coli O157:H7,
isolates or specimens from cases where Shiga toxin activity is
demonstrated);
(L)
Staphylococcus aureus with a vancomycin minimum inhibition
concentration (MIC) greater than 2 micrograms per milliliter
(µg/mL);
(M) all
Streptococcus pneumoniae, invasive, in children under five
years old (Streptococcus pneumoniae from normally sterile sites);
(N) tuberculosis (Mycobacterium
tuberculosis complex);
(O)
tularemia (Francisella tularensis);
(P) vibriosis (Vibrio
species); and
(Q) any outbreak,
exotic disease, or unusual group expression of disease that may be of public
health concern may require submission of cultures or
specimens.
(5) Laboratory
reports. Reports from laboratories must include patient name, identification
number, address, telephone number, age, date of birth, sex, race and ethnicity;
specimen submitter name, address, and phone number; specimen type; date
specimen collected; disease test and test result; normal test range; date of
test report; and physician or practitioner name and telephone
number.
(b) Animals.
(1) Clinically diagnosed or
laboratory-confirmed animal cases of the following diseases are reportable:
anthrax, arboviral encephalitis, tuberculosis (Mycobacterium
tuberculosis complex) in animals other than those housed in research
facilities, and plague. All non-negative rabies tests performed on animals from
Texas at laboratories located outside of Texas must be reported. All
non-negative rabies tests performed in Texas must be reported by the laboratory
conducting the testing. In addition to individual case reports, any outbreak,
exotic disease, or unusual group expression of disease which may be of public
health concern should be reported by the most expeditious means.
(2) The minimal information that must be
reported for each disease includes species and number of animals affected,
disease or condition, name and phone number of the veterinarian or other person
in attendance, and the animal owner's name, address, and phone number. Other
information may be required as part of an investigation in accordance with
Texas Health and Safety Code §
81.061.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.